VIVUS, Inc. (VVUS) Extends Olive Branch, Follows With Fist

VIVUS, Inc. (NASDAQ:VVUS)Oh, what a difference a day makes.

On Saturday, VIVUS, Inc. (NASDAQ:VVUS) extended an olive branch to its largest shareholder and proxy-fight-adversary First Manhattan, offering to give the hedge fund three board seats whether First Manhattan won seats or not.

Trying to compromise is a good idea, one that I suggested a few weeks ago. Shares have nearly quadrupled since Biogen Idec Inc (NASDAQ:BIIB) ended its proxy fight with investor Carl Icahn by giving one of his nominees a seat on the board. I doubt Icahn’s nominee had that much influence on the success, given that there are 12 directors on the board. But not facing a proxy fight almost certainly helped Biogen Idec Inc (NASDAQ:BIIB) recruit CEO George Scangos, who arguably did have a lot to do with the success.

VIVUS, Inc. (NASDAQ:VVUS)’ niceness was short-lived, though, with the company claiming Sunday that it had reported First Manhattan to the SEC for “false and misleading statements.” The company didn’t actually say what First Manhattan had said except to point out that it was regarding statements about the recommendation of Institutional Shareholder Services, which recommended voting for three of First Manhattan’s nominees.

VIVUS, Inc. (NASDAQ:VVUS) used the issue as a reason (excuse) to delay Monday’s stockholders’ meeting until Thursday. First Manhattan countered suing VIVUS, asking the court to order the inspector of elections to certify the results based on the results that were prepared to be voted at the meeting on July 15.

I doubt the court will agree; for most annual meetings, shareholders have the right to vote at the meeting, so how can we know how shareholders would have ultimately voted if the meeting never occurred?

It seems clear from their actions, though, that both sides believe First Manhattan is leading the proxy fight. No one knows what’s next, but I doubt it’ll involve any compromises.

The real winner
The longer this drags on, the better it is for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Eisai, which sell the obesity drug Belviq that competes directly with VIVUS, Inc. (NASDAQ:VVUS)’ Qsymia. With management and employees distracted by the proxy fight, I doubt marketing of the drug is firing on all cylinders.

If First Manhattan wins, the hedge fund has made it clear it plans to replace CEO Leland Wilson with Anthony Zook, the former president of MedImmune. Even if the switch can take place fairly quickly, it’ll take time to get the new strategy implemented.

Depending on how well VIVUS, Inc. (NASDAQ:VVUS) recovers from the turmoil, the proxy fight could even benefit Orexigen Therapeutics, Inc. (NASDAQ:OREX), which has an obesity drug that could be on the market next year.

If VIVUS, Inc. (NASDAQ:VVUS) somehow pulls a come-from-behind victory, I expect that shares might drop substantially since it seems clear there’s a sizable shareholder base looking for a change.

Investors might also vote in some, but not all, of First Manhattan’s nominees, which would seem to be the worst outcome for VIVUS and therefore the best for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc. (NASDAQ:OREX). Internal boardroom fighting would certainly hinder the long-term prospects for Qsymia.

The article VIVUS Extends Olive Branch, Follows With Fist originally appeared on Fool.com and is written by Brian Orelli.

Fool contributor Brian Orelli has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

10 Top Reasons For Getting Fired

The 3 Best States to Start an LLC

10 Jobs That Allow You to Travel

7 High-Paying Jobs You Can Do From Home

12 Best Cities to Shop in USA

10 Best States To Practice Medicine

The 10 Best States to Have a Business

The 12 Most Expensive Apple (AAPL) Apps in the Market

The 10 Richest Billionaires in the World

10 Biggest Kickstarter Failures

The 10 Best Places to Work At

The Top 10 of Google Inc (GOOGL)’s Most Expensive Acquisitions

13 Best Cities to Visit in South America

10 Most Expensive Works of Art of All Time

The 10 Richest Banks in the World

The 10 Best-Paying Jobs in America (2014)

7 Most Expensive Foods in the World

The World’s Top 10 Earning Authors

Five Wicked and Very Expensive Items (and Other “Stuff”) Sold on eBay

10 Biggest Celebrity Bankruptcies

The Top 10 Highest Paid CEOs in 2014

The 10 Most Expensive Real Estate Cities in America

10 Most Expensive States To Live In America

The 10 Best Airlines in the World

The 10 Best-Selling Cars in 2014

The 10 Best Industries to Invest In

The 10 Most Expensive States to Own a Car In

Top 10 Business Schools in US: 2014 Rankings

Top 20 Female Billionaires in 2014

6 Movies That You Should Watch to Better Understand The Cold War

Top 15 Best Paying Jobs for Women in 2014

Top 6 Things Rich People Do Differently Every Day

5 Retirement Mistakes To Avoid (and Einstein’s Famous Quote)

11 Smartest People in the World

6 Films About the Financial World You Need To Watch (While “The Wolf” is Not Around)

Warren Buffett and Billionaires Are Crazy About These 7 Stocks

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!